Agents under investigation for the treatment and prevention of neutropenia

• LYMAN GH, DELGADO D: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin's lymphoma. Cancer (2003) 98:2402-2409.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, DALE DC, KUDERER NM et al.: Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J. Natl. Compr. Cancer Netw. (2007) (In Press).
   Google Scholar
• LYMAN GH, LYMAN CH, AGBOOLA O: Risk models for predicting chemotherapy-induced neutropenia. Oncologist (2005) 10:427-437.
   PubMed Web of Science ®Google Scholar
• KUDERER NM, DALE DC, CRAWFORD J, COSLER LE, LYMAN GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 106(10):2258-2266.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, DALE DC, CRAWFORD J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J. Clin. Oncol. (2003) 21(24):4524-4531.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, DALE DC, FRIEDBERG J, CRAWFORD J, FISHER RI: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J. Clin. Oncol. (2004) 22(21):4302-4311.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, OZER H, STOLLER R et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Engl. J. Med. (1991) 325(3):164-170.
   PubMed Web of Science ®Google Scholar
• KUDERER NM, DALE DC, CRAWFORD J, LYMAN GH: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review and meta-analysis. J. Clin. Oncol. (2007) 21:3158-3167.
   Google Scholar
• KOMROKJI RS, LYMAN GH: The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin. Biol. Ther. (2004) 4(12):1897-1910.
   PubMed Web of Science ®Google Scholar
• LYMAN GH: Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opin. Biol. Ther. (2005) 5(12):1635-1646.
   PubMed Web of Science ®Google Scholar
• SHAYNE M, CRAWFORD J, DALE DC, CULAKOVA E, LYMAN GH: Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res. Treat. (2006) 100(3):255-262.
   PubMed Web of Science ®Google Scholar
• SMITH TJ, KHATCHERESSIAN J, LYMAN GH et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. (2006) 24(19):3187-3205.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, ALTHAUS B, ARMITAGE J et al.: Myeloid growth factors. Clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. (2007) 5(2):188-202.
   PubMedGoogle Scholar
• AAPRO MS, CAMERON DA, PETTENGELL R et al.: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur. J. Cancer (2006) 42(15):2433-2453.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, KLEINER JM: Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J. Natl. Compr. Cancer Netw. (2007) 5(2):217-228.
   PubMedGoogle Scholar
• LYMAN GH, LYMAN CG, SANDERSON RA, BALDUCCI L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J. Natl. Cancer Inst. (1993) 85(6):488-493.
   PubMed Web of Science ®Google Scholar
• LYMAN GH, KUDERER N, GREENE J, BALDUCCI L: The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur. J. Cancer (1998) 34(12):1857-1864.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, GRIFFIN JD: Granulocyte colony-stimulating factor and its receptor. Blood (1991) 78(11):2791-2808.
   PubMed Web of Science ®Google Scholar
• ROOT RK, DALE DC: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J. Infect. Dis. (1999) 179(Suppl. 2):S342-S352.
   PubMed Web of Science ®Google Scholar
• LIESCHKE GJ, BURGESS AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N. Engl. J. Med. (1992) 327(1):28-35.
   PubMed Web of Science ®Google Scholar
• LIESCHKE GJ, BURGESS AW: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N. Engl. J. Med. (1992) 327(2):99-106.
   PubMed Web of Science ®Google Scholar
• EMA H, SUDA T, MIURA Y, NAKAUCHI H: Colony formation of clone-sorted human hematopoietic progenitors. Blood (1990) 75(10):1941-1946.
   PubMed Web of Science ®Google Scholar
• BEGLEY CG, NICOLA NA, METCALF D: Proliferation of normal human promyelocytes and myelocytes after a single pulse stimulation by purified GM-CSF or G-CSF. Blood (1988) 71(3):640-645.
   PubMed Web of Science ®Google Scholar
• BARREDA DR, HANINGTON PC, BELOSEVIC M: Regulation of myeloid development and function by colony stimulating factors. Dev. Comp. Immunol. (2004) 28(5):509-554.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI M, TSUTSUMI H, KUMAKAWA T et al.: Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood (1990) 76(10):1962-1964.
   PubMed Web of Science ®Google Scholar
• LIESCHKE GJ, GRAIL D, HODGSON G et al.: Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood (1994) 84(6):1737-1746.
   PubMed Web of Science ®Google Scholar
• NILSSON SK, LIESCHKE GJ, GARCIA-WIJNEN CC et al.: Granulocyte-macrophage colony-stimulating factor is not responsible for the correction of hematopoietic deficiencies in the maturing op/op mouse. Blood (1995) 86(1):66-72.
   PubMedGoogle Scholar
• COLOTTA F, RE F, POLENTARUTTI N, SOZZANI S, MANTOVANI A: Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood (1992) 80(8):2012-2020.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, ANTMAN KH: Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations. Semin. Oncol. (1992) 19(4):362-385.
   PubMed Web of Science ®Google Scholar
• COREY SJ, BURKHARDT AL, BOLEN JB et al.: Granulocyte colony-stimulating factor receptor signaling involves the formation of a three-component complex with Lyn and Syk protein-tyrosine kinases. Proc. Natl. Acad. Sci. USA (1994) 91(11):4683-4687.
   PubMed Web of Science ®Google Scholar
• LARSEN A, DAVIS T, CURTIS BM et al.: Expression cloning of a human granulocyte colony-stimulating factor receptor: a structural mosaic of hematopoietin receptor, immunoglobulin, and fibronectin domains. J. Exp. Med. (1990) 172(6):1559-1570.
   PubMed Web of Science ®Google Scholar
• GERMESHAUSEN M, BALLMAIER M, WELTE K: Implications of mutations in hematopoietic growth factor receptor genes in congenital cytopenias. Ann. NY Acad. Sci. (2001) 938:305-320; discussion 320-301.
   PubMed Web of Science ®Google Scholar
• LANZA F, RIGOLIN GM, CASTAGNARI B, MORETTI S, CASTOLDI G: Potential clinical applications of rhGM-CSF in acute myeloid leukemia based on its biologic activity and receptor interaction. Haematologica (1997) 82(2):239-245.
   PubMedGoogle Scholar
• MOGHIMI SM, HUNTER AC: Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. (2000) 18(10):412-420.
   PubMed Web of Science ®Google Scholar
• ROSHDY MN, SCHNAARE RL, SCHWARTZ JB: The effect of formulation composition and dissolution parameters on the gel strength of controlled release hydrogel tablets. Pharmaceut. Dev. Technol. (2001) 6(4):583-593.
   PubMed Web of Science ®Google Scholar
• ROBINSON SN, CHAVEZ JM, BLONDER JM et al.: Hematopoietic progenitor cell mobilization in mice by sustained delivery of granulocyte colony-stimulating factor. J. Interferon Cytokine Res. (2005) 25(8):490-500.
   PubMed Web of Science ®Google Scholar
• COX GN, SMITH DJ, CARLSON SJ et al.: Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp. Hematol. (2004) 32(5):441-449.
   PubMed Web of Science ®Google Scholar
• DOHERTY DH, ROSENDAHL MS, SMITH DJ et al.: Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjugate Chem. (2005) 16(5):1291-1298.
   PubMed Web of Science ®Google Scholar
• TALMADGE JE, CHAVEZ JM, BLONDER JM, ROSENTHAL GJ, ROBINSON SN: Increased bioactivity by G-CSF formulated in a matrix with sustained release and marrow-targeting characteristics. Blood (2002) 100(11):5240.
   Google Scholar
• BLONDER JM, ROBINSON SN, CHAVEZ JM et al.: G-CSF forumlated in a pluronic-based matrix shows extended pharmacokinetics and enhanced hematopoeitic activity. Blood (2001) 98(11):1251.
   Google Scholar
• CHAMOW SM, ASHKENAZI A: Immunoadhesins: principles and applications. Trends Biotechnol. (1996) 14(2):52-60.
   PubMed Web of Science ®Google Scholar
• DEFREES S, WANG ZG, XING R et al.: GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology (2006) 16(9):833-843.
   Google Scholar
• ZAMBONI WC: Pharmacokinetics of pegfilgrastim. Pharmacotherapy (2003) 23(8 Part 2):S9-S14.
   Google Scholar
• AUCI D, NICOLETTI F, MANGANO K et al.: Anti-inflammatory and immune regulatory properties of 5-androsten-3-β, 15β-diol (HE2100) and synthetic analogue HE3204: implications for treatment of autoimmune diseases. Ann. NY Acad. Sci. (2005) 1051:730-742.
   PubMed Web of Science ®Google Scholar
• UETRECHT J: Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J. (2005) 7:E914-E921.
   Web of Science ®Google Scholar
• DOWDING C, FRINCKE J, GARSD A, STICKNEY DR, READING CL: Administration of an HE2100 depot preparation after 60Co total body irradiation (400 cGy) reduces the duration of severe neutropenia, thrombocytopenia and anemia in rhesus macaques. Blood (2004) 104(11):1461.
   Google Scholar
• WHITNALL MH, ELLIOTT TB, HARDING RA et al.: Androstenediol stimulates myelopoiesis and enhances resistance to infection in γ-irradiated mice. Int. J. Immunopharmacol. (2000) 22(1):1-14.
   PubMed Web of Science ®Google Scholar
• STICKNEY DR, DOWDING C, GARSD A et al.: 5-Androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression. Int. Immunopharmacol. (2006) 6(11):1706-1713.
   PubMed Web of Science ®Google Scholar
• STICKNEY DR, DOWDING C, READING C, FRINCKE J: HE2100 and HE3204 protect rhesus macaques from chemotherapy or radiation induced myelosuppression. Proc. Am. Soc. Clin. Oncol. (2004) 22(14S):6668.
   Google Scholar
• STICKNEY DR, DOWDING C, AUTHIER S et al.: HE2100 (androst-5-ene-3{β}, 17{β}-diol), an adrenal hormone, protects rhesus macaques from lethal total body irradiation (TBI)-induced severe neutropenia and thrombocytopenia. Blood (2005) 106(11):5223.
   Google Scholar
• KAYA-AERTS FSF, VISSER TP, READING CL et al.: HE2100 (5-androstene-3{β},17{β}-diol) after cytoreductive total body irradiation of rhesus monkeys promotes the recovery of immature CD34+ bone marrow cells, accelerates platelet, granulocyte and red cell reconstitution, and alleviates neutropenia and anemia. Blood (2005) 106(11):4203.
   Google Scholar
• STICKNEY DR, DOWDING C, READING C et al.: HE2100 protects irradiated rhesus macaques against ‘hematopoietic syndrome’. Blood (2003) 102(11):20.
   Google Scholar
• GAGNON L, BARABE J, LAGRAOUI M et al.: PBI-1402: a new candidate for the treatment of anemia. Blood (2006) 108(11):4223.
   PubMed Web of Science ®Google Scholar
• GROUIX B, JULIEN N, LAGRAOUI M et al.: PBI-1402: a low molecular weight synthetic hematopoietic growth stimulant. Blood (2006) 108(11):4222.
   Google Scholar
• LAGRAOUI M, GROUIX B, JULIEN N et al.: PBI-1402: a non-toxic immunorestorative small molecule for the treatment of anemia. Blood (2006) 108(11):4224.
   Google Scholar
• MORIN M-J, KROSL G, LAGRAOUI M et al.: Oral administration of PBI-1402 significantly reduces erythropenia and accelerates peripheral blood recovery in myeloablated mice post transplantation. Blood (2006) 108(11):3201.
   Google Scholar
• TEMURA M, GU J, TAKINO T, YAMADA KM: Tumor suupressor PTEN inhibition of cell invasion, migration and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. (1999) 59:442-449.
   PubMed Web of Science ®Google Scholar
• HERBERT KE, WALKLEY CR, WINKLER IG et al.: Granulocyte colony-stimulating factor and an RARα specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells. Transplantation (2007) 83(4):375-384.
   PubMed Web of Science ®Google Scholar
• TSAI S, COLLINS SJ: A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage. Proc. Natl. Acad. Sci. USA (1993) 90(15):7153-7157.
   PubMed Web of Science ®Google Scholar
• HUANG ME, YE YC, CHEN SR et al.: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 72(2):567-572.
   PubMed Web of Science ®Google Scholar
• WARRELL RP Jr, DE THE H, WANG ZY, DEGOS L: Acute promyelocytic leukemia. N. Engl. J. Med. (1993) 329(3):177-189.
   PubMed Web of Science ®Google Scholar
• DEGOS L, DOMBRET H, CHOMIENNE C et al.: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood (1995) 85(10):2643-2653.
   PubMed Web of Science ®Google Scholar
• DOUER D, KOEFFLER HP: Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. Exp. cell Res. (1982) 138(1):193-198.
   PubMed Web of Science ®Google Scholar
• BEARD RL, DUONG TT, TENG M et al.: Synthesis and biological activity of retinoic acid receptor-α specific amides. Bioorg. Med. Chem. Lett. (2002) 12(21):3145-3148.
   PubMed Web of Science ®Google Scholar
• WALKLEY CR, PURTON LE, SNELLING HJ et al.: Identification of the molecular requirements for an RARα-mediated cell cycle arrest during granulocytic differentiation. Blood (2004) 103(4):1286-1295.
   PubMed Web of Science ®Google Scholar
• TAYLOR CW, TANG-LIU D, GOERMAR N: A Phase I and phamacokinetic clinical trial of the orally administered retinoic acid receptor-α agonist, AGN 195183. (2001):298.
   Google Scholar
• ROLLINS BJ: Chemokines. Blood (1997) 90(3):909-928.
   PubMed Web of Science ®Google Scholar
• TAUB DD, OPPENHEIM JJ: Chemokines, inflammation and the immune system. Ther. Immunol. (1994) 1(4):229-246.
   PubMedGoogle Scholar
• LUSTER AD: Chemokines–chemotactic cytokines that mediate inflammation. N. Engl. J. Med. (1998) 338(7):436-445.
   PubMed Web of Science ®Google Scholar
• KIM HK, DE LA LUZ SIERRA M, WILLIAMS CK, GULINO AV, TOSATO G: G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood (2006)108(3):812-820.
   PubMed Web of Science ®Google Scholar
• PETIT I, SZYPER-KRAVITZ M, NAGLER A et al.: G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. (2002) 3(7):687-694.
   PubMed Web of Science ®Google Scholar
• LILES WC, BROXMEYER HE, RODGER E et al.: Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood (2003) 102(8):2728-2730.
   PubMed Web of Science ®Google Scholar
• DEVINE SM, FLOMENBERG N, VESOLE DH et al.: Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. (2004) 22(6):1095-1102.
   PubMed Web of Science ®Google Scholar
• ELDAR-LISSAI A, COSLER LE, CULAKOVA E, LYMAN GH: Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2007) (In Press).
   Google Scholar
• BUCANEVE G, MICOZZI A, MENICHETTI F et al.: Levofloaxacin to prevent bacterial infection in patients with cancer and neutropenia. N. Engl. J. Med. (2005) 353:977-987.
   PubMed Web of Science ®Google Scholar
• HUGHES T, ARMSTRONG D, BODEY GP et al.: 2002 Guidelines for the use of antimicrobial agents in neutropenic cancer patients with cancer. Clin. Infect. Dis. (2002) 200:730-751.
   Google Scholar

Websites

• http://www.maxygen.com/ products-mye.php Next-generation G34 agent in development to treat neutropenia.
   Google Scholar
• http://www.cellerant.com/ tech_clt008_overvw.htm CLT-008: myeloid progenitor cells to treat neutropenia (2006).
   Google Scholar
• http://www.cellerant.com/pdf/pressSeriesB2.pdf Cellerant Therapeutics Press Release (2005).
   Google Scholar